Literature DB >> 5957970

INTRODUCTION

.   

Abstract

Mesh：

Substances：

Year:  1966        PMID： 5957970     DOI： 10.1111/j.1600-0404.1966.tb04768.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  6 in total

1.  Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.

Authors:  Yasuhiro Shimojima; Takahisa Gono; Kanji Yamamoto; Kenichi Hoshi; Masayuki Matsuda; Kunihiro Yoshida; Shu-ichi Ikeda
Journal:  Clin Rheumatol       Date:  2004-03-24       Impact factor: 2.980

2.  Strabismus surgery in the management of diplopia caused by myasthenia gravis.

Authors:  O C Morris; J O'Day
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

3.  A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy.

Authors:  R Mantegazza; E Beghi; D Pareyson; C Antozzi; D Peluchetti; A Sghirlanzoni; V Cosi; M Lombardi; G Piccolo; P Tonali
Journal:  J Neurol       Date:  1990-10       Impact factor: 4.849

4.  Ocular Myasthenia Gravis.

Authors:  Victoria S. Pelak; Steven L. Galetta
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

5.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

6.  Development of myasthenia gravis 8 years after interstitial lung disease associated with antisynthetase (anti-EJ antibody) syndrome.

Authors:  Takashi Ishiguro; Naho Kagiyama; Eriko Kawate; Kyuto Odashima; Yotaro Takaku; Kazuyoshi Kurashima; Noboru Takayanagi
Journal:  Clin Case Rep       Date:  2016-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.